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ABSTRACT
Objective: In healthy women, there is a progressive age-related increase in myocardial mass that is not seen in their male counterparts and 
occurs primarily in postmenopausal women. Raloxifene is a selective estrogen receptor modulator that has estrogenic actions on bone and the 
cardiovascular system. The aim of this study was to investigate the effect of raloxifene on myocardial hypertrophy in postmenopausal patients. 
Methods: A total of 22 postmenopausal osteoporotic women were included in this open-label, randomized, prospective, controlled study. 
Patients were randomized into two groups: 11 of the patients (group 1) were treated with raloxifene 60 mg/day, and the other 11 patients 
(group 2) were defined as the control group. Quantitative 2-dimensional and M-mode echocardiographic examination was performed in all 
patients at the beginning and repeated at the end of the 6-month follow-up period. Left ventricle mass (LVM) and left ventricle mass index (LVMI) 
were calculated for all patients.
Results: The mean age of the patients was 57.2±3.9 years, and baseline clinical characteristics and echocardiographic parameters were similar 
between the two groups. After 6 months of raloxifene treatment, there was no difference in echocardiographic parameters of LVM and LVMI 
compared with the control group (201.2±25.9 gr vs. 169.7±46.2 gr, p=0.14 and 120.4±25.9 gr/m2 vs. 105.5±26.3 gr/m2, p=0.195, respectively). There 
was also no significant difference in LVM and LVMI in the within-group analysis of both groups.
Conclusion: Raloxifene therapy does not affect myocardial hypertrophy in postmenopausal women after 6 months of treatment.
(Anatol J Cardiol 2015; 15: 480-4)
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Introduction
In postmenopausal women, left ventricular hypertrophy is 
common and is likely to be a strong cardiovascular risk factor 
compared with men, suggesting that estrogen has potential pro-
tective effects in the cardiovascular system (1). There are sub-
stantial gender differences in myocardial remodeling due to the 
influence of sex hormones. Left ventricular hypertrophy is asso-
ciated with an increased risk of cardiovascular morbidity and 
mortality in women (1).
In the general population, there is a progressive age-related 
increase in myocardial mass in healthy women that is not seen 
in their male counterparts (2). These findings were confirmed in 
a healthy, non-obese, normotensive subset of the Framingham 
Heart Study (3). These studies demonstrate that the increase in 
myocardial mass occurs primarily in postmenopausal women. 
Indeed, premenopausal women with essential hypertension 
have thinner posterior left ventricular walls, smaller left ven-
tricular mass, and better cardiac function than age-matched 
men (4).
Elderly (postmenopausal) women with systolic hypertension 
or aortic stenosis have more concentric remodeling and better 
preserved left ventricular systolic function than their male coun-
terparts both at rest and with exercise (5, 6). These data suggest 
that the female sex hormones estrogen and progesterone influ-
ence myocardial hypertrophy and myocardial remodeling by 
suppressing cardiac hypertrophy and preserving myocardial 
function.
Selective estrogen receptor modulators (SERMs) have been 
approved as hormone replacement therapy (HRT) to prevent 
osteoporosis and improve lipid profiles in postmenopausal 
women without producing uterine proliferation (7). Raloxifene is 
a second-generation SERM and exerts estrogen-agonistic 
effects on the cardiovascular system and bone (7). The benefi-
cial effects of raloxifene on cardiovascular risks and events 
have been investigated in the MORE study, and it has been 
shown that raloxifene decreased the risk of cardiovascular 
events among the subset of 1035 women with increased car-
diovascular risk at baseline, compared with placebo (8). 
However, in the RUTH study, raloxifene did not significantly 
affect the risk of coronary heart disease in patients with high 
risk for major coronary events based on established cardiovas-
cular disease (9).
The knowledge about the effects of raloxifene on myocardial 
hypertrophy in postmenopausal women is scant in the literature, 
and we aimed to investigate the effect of raloxifene on myocar-
dial hypertrophy in this study.
Methods
This study was designed as a prospective-randomized-con-
trolled study according to the CONSORT statement, and institu-
tional review board approval was obtained from the Ethics 
Committee of Başkent University. Subjects were recruited from 
the Menopause Clinic of the Department of Obstetrics and 
Gynecology. All postmenopausal [at least 12 months elapsed 
from the last spontaneous menstrual bleeding. and each partici-
pant exhibited a serum follicle-stimulating hormone (FSH) level 
>40 U/L and an estradiol (E2) level <30 pg/mL] and osteoporotic 
[T-score for femoral neck or lumbar spine bone mineral density 
(BMD) measurements ≤2.5 standard deviation (SD) according to 
the results of dual-energy x-ray absorptiometry] women with 
endometrial thickness ≤5 mm in ultrasound imaging were evalu-
ated for the study. Exclusion criteria were defined as: history of 
gynecologic malignancy, ischemic heart disease, heart failure, 
hypertrophic cardiomyopathy, aortic stenosis, thromboembo-
lism, abnormal liver function, renal dysfunction, epilepsy, severe 
migraines, non-treated thyroid dysfunction, and patients treated 
with hormone therapy during the 3 months before the initiation 
of the study. A total of 22 postmenopausal osteoporotic women 
(age range, 51-70 years) were included in the study. A table of 
randomly generated numbers was used for randomization. 
Patients were randomized into two groups: group 1 (n: 11) was 
treated with raloxifene 60 mg/day, and group 2 (n: 11) was 
defined as the control group; all of the patients received 600 mg 
calcium daily + 400 IU vitamin D, an over-the-counter product. 
All subjects signed an informed consent form. 
Hypertension was defined as systolic blood pressure ≥140 
mm Hg, diastolic blood pressure ≥90 mm Hg, or both or the use 
of antihypertensive medication for the study purpose according 
to the 2013 guidelines of the European Society of Hypertension 
(ESH) and the European Society of Cardiology (ESC) task force 
for the management of arterial hypertension (10). Diabetes was 
defined as fasting glucose level >126 mg on at least 2 occasions 
or current use of anti-diabetic agents (11). Patients who were 
currently smoking cigarettes were considered smokers. BMI 
was calculated as weight (kilogram or kg) divided by height 
(meter or m) squared (kg/m2).
Echocardiographic examination
All patients underwent an echocardiographic examination, 
including quantitative 2-dimensional and M-mode echocardio-
graphic examination by means of an echocardiography unit with 
a 3.5-MHz transducer (Siemens Acuson Sequa c256, Munich, 
Germany). Echocardiograms were obtained by the same cardi-
ologist after each patient was placed in the left lateral decubitus 
position. To reduce bias, the cardiologist was blinded to the 
patient groups. Measurements for M-mode-guided calculation 
of left ventricular mass (LVM) were taken in the parasternal 
short-axis view and were recorded at the papillary level. Left 
ventricular internal dimensions at end-diastole (LVIDd) and sep-
tal (SWTd) and posterior wall thickness at end-diastole (PWTd) 
were measured. LVM was calculated by the American Society 
of Echocardiography (ASE)-recommended formula (12) LVM(g) = 
0.8 × {1.04 × [(LVIDd + PWTd + SWTd)3 - (LVIDd)3]} + 0.6 and 
standardized to body size by dividing the raw LVM by body sur-
face area as left ventricular mass index (LVMI). A second echo-
cardiographic evaluation was conducted after the sixth month of 
the treatment, and all measurements were repeated.
Statistical analysis
The statistical package SPSS (Statistical Package for the 
Social Sciences, version 17.0, SSPS Inc, Chicago, Ill, USA) was 
used for statistical analyses. Continuous variables are expressed 
as mean±SD. All continuous variables were checked with 
Kolmogorov-Smirnov normality test to show their distributions. 
Continuous variables with normal distributions were compared 
using the unpaired student t-test. Continuous variables with 
abnormal distributions were compared using the Mann-Whitney 
U test. The chi-square test was used for categorical variables. P 
values of less than .05 were considered statistically significant. 
Changes in the echocardiographic measurements from baseline 
to those recorded at the end of the sixth month of the study were 
evaluated by means of the paired-sample t-test.
Results
The mean age of the two groups was 57.8±4.5 vs. 56.6±3.4 
years (p=0.494). Gravidity and parity of the patients were not dif-
ferent between the groups (p=0.897 and p=0.627, respectively). 
Baseline laboratory parameters and clinical features were simi-
lar in both groups (Table 1). All patients completed the follow-up 
period of 6 months.
The baseline echocardiographic parameters were similar, 
and ejection fraction was normal in both groups (p=0.835). There 
was no significant within-group changes in echocardiographic 
parameters of LVM and LVMI at the end of the 6-month follow-
up period in both groups (group 1: p=0.919 and p=0.915, respec-
tively; group 2: p=0.194 and p=0.147, respectively). Also, these 
echocardiographic parameters (LVM and LVMI) did not differ 
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between the raloxifene group compared with control group at 
baseline and the 6th month (p=0.14 and p=0.195, respectively). 
The other echocardiographic parameters were also similar in 
the between- and within-group analyses at the end of the study 
(Table 2).
Discussion
In this prospective, randomized, controlled study, we studied 
the association between raloxifene use and LVMI determined by 
echocardiography in postmenopausal women, and we did not 
find any effect of raloxifene on left ventricle hypertrophy in the 
6-month follow-up period.
It is known that estrogen receptors are present in the myo-
cardium (13), and there are controversial data in the literature 
about the effect of HRT on LVM and LVMI. In contrast with our 
study, Lim et al. (14) showed that women who were using HRT 
for more than 10 years had a significant reduction in septal and 
posterior left ventricular wall thickness when compared with 
controls. In an autopsy study, Olivetti et al. (15) demonstrated 
that myocyte number and volume are better preserved in women 
than in men. This intriguing study is supported by findings that 
estrogen may be important in the activation of the antiapoptotic 
AKT (protein kinase B) kinase in the heart (16). Thus HRT, and 
particularly estrogen, positively affects myocardial hypertrophy 
and remodeling, and this mechanism seems to be the most plau-
sible explanation for the improved survival with HRT in women 
with advanced heart failure (17).
However, some studies were consistent with our findings. 
Snabes et al. (18) examined the effect of E2 replacement ther-
apy on cardiac structure and function in healthy postmeno-
pausal women, and they found that E2 replacement therapy, 
which results in physiological serum concentrations, does not 
affect cardiac structure or function in normal postmenopausal 
women after 12 weeks of treatment. In a prospective, con-
trolled study, Kessel et al. (19) studied the short- and interme-
diate-term effects of low-dose HRT on echocardiographic 
parameters of cardiac function in healthy postmenopausal 
women, and they did not find any clinically relevant differenc-
es in M-mode, quantitative 2-dimensional, and Doppler echo-
cardiographic parameters within 15 months of 17 beta-estradi-
ol and dydrogesterone treatment. Recently, Schwarz et al. (20) 
analyzed the association between HRT and either LVMI, deter-
mined echocardiographically, in a cross-sectional study, and 
they did not find any significant associations with LVH after full 
adjustment. However, all of these studies were performed by 
using non-selective estrogens or did not consider what the 
patients were treated with. 
Selective estrogen receptor modulators bind to and alter 
estrogen receptor function by inhibiting the binding of endoge-
nous estrogens and can be conveniently divided into different 
categories (21). Tamoxifen is the prototype of SERMs, and it has 
been shown that tamoxifen can cause severe dilated cardiomy-
opathy in animal models (22, 23). Raloxifene is a second-gener-
ation SERM that is used for the same indication but has a differ-
ent mechanism of action by comparison with tamoxifen. 
Conversely, raloxifene increases myocyte contraction and was 
not associated with an increased risk of heart failure (24, 25). 
However, the knowledge in the literature about the effect of ral-
oxifene on myocardial hypertrophy is scant.
Two studies performed with raloxifene were consistent with 
our study. In a mouse model, Westphal et al. (26) showed that 
raloxifene did not reduce myocardial hypertrophy but improved 
cardiac function in ovariectomized mice. Similarly, Vogelvang et 
al. (27) performed two studies with a follow-up period of 2 years. 
They found significant within-group changes in some parame-
ters (LVMI, aortic peak flow velocity, and aortic velocity integral) 
from baseline, but interestingly, the same changes occurred in 
the placebo group; so, they found no effect on echocardiograph-
ic parameters of left ventricular systolic function within 2 years 
of raloxifene treatment in healthy postmenopausal women. In 
our study, we also did not find any effect of raloxifene treatment 
on LVM and LVMI, but unlikely, we did not find any difference in 
within-group echocardiographic parameters. A small number of 
our patients were hypertensive and diabetic, and the distribution 
was similar between groups. Antihypertensive and antidiabetic 
treatment of patients during follow-up was unchanged, and all 
 Group 1 Group 2 
Characteristics (n:11) (n:11) P
Age, years 57.8±4.5 56.6±3.4 0.494
Diabetes mellitus, n (%) 2 (18.2) 0 0.138
Hypertension, n (%) 5 (45.5) 3 (27.3) 0.375
Smoking, n (%) 4 (36.4) 1 (9.1) 0.127
Gravida, n 3.0±1.6 2.9±1.6 0.897
Parity, n 1.5±0.7 1.7±1.0 0.627
BMI, (kg/m2) 25.1±2.5 24.8±2.4 0.817
Hemoglobin (g/dL) 13.5±1.2 13.7±1.4 0.819
Creatinine (mg/dL) 0.8±0.3 0.9±0.2 0. 632
Total-C (mg/dL) 226.3±39.6 213.0±43.4 0.462
LDL-C (mg/dL) 144.4±28.6 132.8±33.7 0.392
HDL-C (mg/dL) 54.5±11.1 57.2±16.7 0.657
Triglyceride (mg/dL) 135.8±74.1 118.0±47.0 0.511
CRP 3.0±3.3 1.4±1.4 0.176
Antihypertensive therapy
ACEI/ARB, n (%) 3 (27.3) 1 (9.1) 0.524
Beta-blocker, n (%) 4 (36.4) 2 (9.1) 0.635
CCB, n (%) 1 (9.1) 1 (9.1) 0.524
ACEI - angiotensin-converting enzyme inhibitor; ARB - angiotensin receptor blocker; 
BMI - body mass index; CCB - calcium channel blocker; CRP - C-reactive protein; 
HDL-C - high-density lipoprotein cholesterol; LDL-C - low-density lipoprotein 
cholesterol; Total-C - total cholesterol. 
Independent t-test and Mann-Whitney U-test for baseline characteristics. 
Parametric values given as mean±standard deviation
Table 1. Baseline clinical characteristics and laboratory parameters 
of the groups
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patients’ blood pressure and blood glucose values did not 
change significantly. Therefore, the possible effect of these fac-
tors on LVH was neglected during the study.
Study limitations
The small number of the subjects and the short follow-up 
period were the major limitations of our study. 
Conclusion
Based on our results, we may conclude that raloxifene 
therapy has no effect on left ventricle hypertrophy in healthy 
postmenopausal women. But, there is still a need for larger and 
long-term studies to draw firm conclusions.
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